drugset / Trial / NCT02432976

Impact of Perioperative Exenatide Infusion on Quality of Life in Cardiac Surgery Patients

NCT02432976

RandomizedParallel-groupOpen-labelTreatment

Summary

A diminution of quality of life is often reported by patients after coronary artery bypass graft (CABG) surgery. A part of this diminution could be explain by postoperative left ventricular (LV) dysfunction. Exenatide (Byetta®) is an incretin mimetic, characterized by an anti-hyperglycemic effect that depends on the blood glucose level. Recent data have suggested that exenatide could improve LV function by an inotropic effect in patients suffering from cardiogenic shock or from congestive heart failure. Moreover, patients suffering from congestive heart failure reported a better quality of life when they were treated with exenatide compared to placebo. The investigators hypothesize that perioperative exenatide infusion could improve postoperative quality of life in CABG surgery patients.

Timeline

Start
2015-05
Primary completion
2017-01
Completion
2017-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Exenatide Peptide 0.025 ug Intravenous
Comparator Insulin Protein / enzyme biologic Intravenous

Indications

No indication recorded.